Yuichi Ozawa

1.6k total citations
62 papers, 1.1k citations indexed

About

Yuichi Ozawa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yuichi Ozawa has authored 62 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Yuichi Ozawa's work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Yuichi Ozawa is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Yuichi Ozawa collaborates with scholars based in Japan, United States and Taiwan. Yuichi Ozawa's co-authors include Takafumi Suda, Naoki Inui, Kingo Chida, Noriyuki Enomoto, Hirotoshi Nakamura, Yutaro Nakamura, Takashi Matsui, Dai Hashimoto, Tateaki Naito and Tomoyuki Fujisawa and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Yuichi Ozawa

55 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuichi Ozawa Japan 16 640 493 192 159 155 62 1.1k
Yoshiko Kaneko Japan 17 508 0.8× 630 1.3× 241 1.3× 173 1.1× 69 0.4× 59 1.1k
Kakuhiro Yamaguchi Japan 15 470 0.7× 222 0.5× 96 0.5× 101 0.6× 84 0.5× 93 751
Katsushi Kurosu Japan 16 575 0.9× 144 0.3× 163 0.8× 240 1.5× 106 0.7× 53 1.0k
Sen Jiang China 17 499 0.8× 194 0.4× 164 0.9× 61 0.4× 133 0.9× 72 977
P J George United Kingdom 17 503 0.8× 439 0.9× 263 1.4× 104 0.7× 50 0.3× 41 1.1k
Tomoyuki Nakagiri Japan 20 618 1.0× 332 0.7× 181 0.9× 50 0.3× 157 1.0× 64 1.3k
Radosław Mlak Poland 17 286 0.4× 250 0.5× 285 1.5× 210 1.3× 52 0.3× 109 892
Yujiro Takai Japan 13 607 0.9× 186 0.4× 114 0.6× 295 1.9× 62 0.4× 63 881
Giacomo Sgalla Italy 16 916 1.4× 74 0.2× 183 1.0× 208 1.3× 98 0.6× 47 1.1k
Susan Mathai United States 19 684 1.1× 71 0.1× 231 1.2× 183 1.2× 119 0.8× 38 1.1k

Countries citing papers authored by Yuichi Ozawa

Since Specialization
Citations

This map shows the geographic impact of Yuichi Ozawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichi Ozawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichi Ozawa more than expected).

Fields of papers citing papers by Yuichi Ozawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichi Ozawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichi Ozawa. The network helps show where Yuichi Ozawa may publish in the future.

Co-authorship network of co-authors of Yuichi Ozawa

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichi Ozawa. A scholar is included among the top collaborators of Yuichi Ozawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichi Ozawa. Yuichi Ozawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ozawa, Yuichi, Yasuhiro Koh, Ryota Shibaki, et al.. (2024). Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer. Cancer Immunology Immunotherapy. 74(1). 7–7. 4 indexed citations
2.
Akamatsu, Hiroaki, Shunsuke Teraoka, Masanori Tanaka, et al.. (2023). A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients. Journal of Pain and Symptom Management. 67(3). 204–211.e1. 3 indexed citations
3.
Ogasawara, Takashi, Naoto Nakamura, Wataru Matsuyama, et al.. (2023). The effect of 1-hydroxy-vitamin D treatment in hospitalized patients with COVID-19: A retrospective study. Clinical Nutrition. 42(10). 2045–2050. 1 indexed citations
4.
Miura, Satoru, Yasuhiro Koh, Koichi Azuma, et al.. (2023). Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC Cancer. 23(1). 6–6. 5 indexed citations
5.
Hayashi, Hidetoshi, Shunichi Sugawara, Yasushi Fukuda, et al.. (2021). A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research. 28(5). 893–902. 49 indexed citations
6.
Akamatsu, Hiroaki, Yuichi Ozawa, Jun Oyanagi, et al.. (2021). Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation. Anticancer Research. 41(2). 911–917. 4 indexed citations
7.
Oyanagi, Jun, Yasuhiro Koh, Koichi Sato, et al.. (2021). Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors. Clinical Lung Cancer. 22(6). e833–e841. 4 indexed citations
8.
Ikeda, Mio, Yasuhiro Koh, Jun Oyanagi, et al.. (2021). High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter. Anticancer Research. 42(1). 407–417. 3 indexed citations
9.
Ozawa, Yuichi, Toyoharu Yokoi, Kōichi Nakamura, et al.. (2020). Secondary bladder cancer arising after iodine-125 permanent seed implantation for localized prostate cancer. European Urology Open Science. 19. e2118–e2119.
10.
11.
Nakashima, Kazuhisa, Hiroaki Akamatsu, Haruyasu Murakami, et al.. (2019). Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. Anticancer Research. 39(3). 1463–1468. 4 indexed citations
12.
Akamatsu, Hiroaki, Yasuhiro Koh, Yuichi Ozawa, et al.. (2018). Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. Clinical Lung Cancer. 19(6). e871–e874. 12 indexed citations
13.
14.
Ozawa, Yuichi, Yusuke Amano, Yoshiko Sato, et al.. (2017). Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Respiratory Investigation. 56(2). 179–183. 4 indexed citations
15.
Enomoto, Yasunori, Naoki Inui, Shiro Imokawa, et al.. (2015). Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Cancer Chemotherapy and Pharmacology. 76(3). 499–505. 18 indexed citations
16.
Ozawa, Yuichi, Takashi Matsui, Masato Kato, et al.. (2015). Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer. PLoS ONE. 10(10). e0140437–e0140437. 50 indexed citations
17.
Matsuura, Shun, Naoki Inui, Yuichi Ozawa, et al.. (2011). Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations. Japanese Journal of Clinical Oncology. 41(8). 959–963. 12 indexed citations
18.
Ozawa, Yuichi, Takafumi Suda, Tateaki Naito, et al.. (2009). Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 14(5). 723–728. 221 indexed citations
19.
Suzaki, Yuki, Masanori Yoshizumi, Shoji Kagami, et al.. (2004). BMK1 is activated in glomeruli of diabetic rats and in mesangial cells by high glucose conditions. Kidney International. 65(5). 1749–1760. 53 indexed citations
20.
Ozawa, Yuichi, et al.. (1999). Plasma Levels of Free and Sulfoconjugated Catecholamines in Patients with Atherosclerosis.. Biological and Pharmaceutical Bulletin. 22(6). 657–659. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshiko Kaneko Breakdown of academic impact, for papers by Kakuhiro Yamaguchi Breakdown of academic impact, for papers by Katsushi Kurosu Breakdown of academic impact, for papers by Sen Jiang Breakdown of academic impact, for papers by P J George Breakdown of academic impact, for papers by Tomoyuki Nakagiri Breakdown of academic impact, for papers by Radosław Mlak Breakdown of academic impact, for papers by Yujiro Takai Breakdown of academic impact, for papers by Giacomo Sgalla Breakdown of academic impact, for papers by Susan Mathai
Rankless by CCL
2026